PTJ
PLSE icon

Paul Tudor Jones’s Pulse Biosciences PLSE Stock Holding History

Paul Tudor Jones’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,791
Closed -$382K – 4137
2025
Q4 		$382K Buy
+27,791
New +$433K ﹤0.01% 2885

Other funds holding PLSE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Paul Tudor Jones's PLSE Position: Q1 2026 in Review

Paul Tudor Jones sold out of Pulse Biosciences (PLSE) in Q1 2026, closing a stake of 27,791 shares — an estimated $382K sold.

Paul Tudor Jones first reported a position in PLSE in Q4 2025 and held it in 1 quarter. The position peaked at $382K in Q4 2025. 96 funds tracked by Wall St. Rank hold PLSE as of Q1 2026.

  • Paul Tudor Jones reported no remaining Pulse Biosciences position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 27,791 Pulse Biosciences shares in Q1 2026, an estimated $382K.
  • Paul Tudor Jones first reported a position in Pulse Biosciences in Q4 2025 and held it in 1 quarter.
  • Paul Tudor Jones's Pulse Biosciences position peaked at $382K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Pulse Biosciences as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.